google.com, pub-8701563775261122, DIRECT, f08c47fec0942fa0
UK

Thousands of Brits prescribed super-strength CANNABIS for mental health conditions including anxiety and depression – with benefits claimants offered free consultations and discounts on their monthly weed prescription

Thousands of Britons are being prescribed super-potent cannabis for anxiety and depression.

Despite warnings from experts about the dangers, private clinics dispense the drug only after a video call and boast that the powerful drug can be ‘delivered directly to the patient’s door via a next-day service’.

At a time when cannabis use is rampant on our streets, an audit by the Daily Mail found specialist pharmacies were prescribing almost 10,000 different products; These include ultra-strong strains imported from Amsterdam with names such as Ghost Train Haze, Dante’s Inferno and White Widow.

People seeking help with mental health issues are offered free counseling and up to a 20 percent discount on the cost of medication.

NHS prescriptions are tightly controlled, but 99 per cent of medical cannabis in Britain is distributed by dozens of private clinics.

Cannabis, which the NHS warns greatly increases the risk of serious mental health problems, is routinely prescribed privately for mental health problems such as anxiety, depression, OCD, mood disorders and ADHD.

Those who smoke the drug illegally are even encouraged to contact clinics ‘to see if your use is legitimate’ with a prescription.

The entire process is surprisingly completely legal, thanks to loopholes in the law.

Thousands of Britons are now being prescribed super-potent cannabis for mental health problems such as anxiety and depression, despite an NHS warning it could increase the risk of mental health problems

Leading psychiatrist Professor Sir Robin Murray, of King's College London, described it as an 'outrageous situation'.

Leading psychiatrist Professor Sir Robin Murray, of King’s College London, described it as an ‘outrageous situation’.

A huge increase in high-strength medicinal cannabis distributed over the past few years is raising fears that it is contributing to an increase in mental health problems and psychoses caused by the drug, over-straining the NHS and placing an extra burden on police forces.

The de facto legalization of the drug – with police being told not to arrest people for cannabis possession if there are ‘justifiable grounds’ to believe it may be for medicinal use – has raised concerns that companies taking advantage of lax regulations are creating a bogus recreational market.

Data obtained under the Freedom of Information Act shows there were 88,214 unlicensed cannabis products privately prescribed in the first two months of 2025, the most recent data available.

According to data from the NHS Commercial Services Authority, 659,293 unlicensed cannabis products were prescribed in 2024; this figure was equivalent to almost ten tonnes of grass, down from 282,920 in 2023.

Sir Robin Murray, professor of psychiatric research at King’s College London, described the incident as ‘outrageous’. Stating that the increased potency of the products ‘increases the risk of addiction and psychiatric side effects’, he added: ‘There are no randomized controlled trials showing that cannabis benefits psychiatric disorders, and there is ample evidence that it causes them. It’s a bit like drinking alcohol for depression; Some people think it works in the short term, but in the long term it makes things worse.’

Data from Mamedica, one of the largest private clinics, shows that 50.5 per cent of its more than 12,000 patients in the UK were prescribed cannabis for mental health problems. If this is consistent across the industry, tens of thousands of people are being prescribed medical marijuana for mental health issues.

Some private clinics offer free consultations and discounted ‘weed’ prices to claimants.

Conservative Party health spokesman Stuart Andrew last night called on the Government to act on the Mail’s ‘deeply worrying’ findings. He said: ‘Ministers must take action to tackle this abuse of the system.’

Data obtained under freedom of information legislation shows the total volume of weed prescribed in the UK will rise from 2.7 million grams in 2022 to 9.8 million grams (almost ten tonnes) in 2024 (Stock image)

Data obtained under freedom of information legislation shows the total volume of weed prescribed in the UK will rise from 2.7 million grams in 2022 to 9.8 million grams (almost ten tonnes) in 2024 (Stock image)

A number of private cannabis clinics are offering free advice and discounted pot prices to Universal Credit and Personal Independence Payment (PIP) claimants

A number of private cannabis clinics are offering free advice and discounted pot prices to Universal Credit and Personal Independence Payment (PIP) claimants

Medical marijuana was legalized in 2018 following a campaign to make it available to children with severe epilepsy. Licensed products that do not contain the whole plant can be prescribed on the NHS for severe epilepsy, nausea caused by chemotherapy or muscle spasms caused by multiple sclerosis.

However, private clinics can legally prescribe unlicensed products that have not undergone strictly controlled medical trials.

Dozens of specialty pharmacies offer products with more than 30 percent THC (psychoactive ingredient) content. Freedom of Information data shows projected volume rising from 2.7 million grams in 2022 to 9.8 million grams in 2024.

It also shows an increase in the number of people being prescribed high-potency cannabis. The most popular potency in 2022 was between 18 and 22 percent THC, but in the first two months of 2025, products above 22 percent accounted for nearly half of prescriptions.

Mamedica said it prescribes based on a ‘strictly regulated clinical and legal framework’ where all prescriptions are issued by a registered doctor in accordance with the Home Office, MHRA and CQC and requirements. A spokesman said: ‘Prescribing is done on a patient-by-patient basis by specialist clinicians and is carried out under established medicines law and regulatory oversight.

‘Mental health is one of the most common reasons why patients seek specialist care after conventional treatments have failed. ‘Patients presenting with disorders such as anxiety, PTSD and depression are assessed individually and managed within strict protection and collaborative care protocols.’

A government spokesman said: ‘We expect regulators to crack down on private providers who prescribe to patients who do not have the clinical care they need.

‘More broadly, we also address private prescribing to ensure patients have access to high-quality medicines through all legal channels.’

Prescription marijuana Q&A

How is this possible?

Medical use of cannabis has been legal since November 2018, but only a small number of licensed cannabis products are prescribed by the NHS each year.

Instead, the medical cannabis market has expanded almost entirely through private clinics and pharmacies prescribing products that have not gone through the lengthy process of being licensed for use in Britain.

The Home Office approves special import licenses for cannabis growers and suppliers, the Medicines and Healthcare products Regulatory Agency approves unlicensed medical cannabis products and the Care Quality Commission (CQC) regulates private clinics in England.

Fragmented regulation of the industry means no official body has claimed responsibility for the massive boom in medical marijuana.

Who can take medical marijuana?

Surprisingly, almost everyone. One site says patients often need evidence that they have tried two other medications to treat their condition without success before being prescribed cannabis, but ‘this is up to the prescriber and the discretion of professionals at individual clinics.’

How much cost?

Most clinics charge an initial consultation fee of between £100 and £200; This fee is usually free if you’re on benefits, and prices range from £39.50 for 10g of the cheapest product to £300 for 30g of the most expensive product.

What are ministers doing about this?

The industry has grown so dramatically in 2018, far beyond what was expected, that officials seem either caught off guard or unwilling to take responsibility.

There are some signs that authorities are paying attention. In 2023, the CQC called for a multi-agency review into the impact of the 2018 law change on medical cannabis.

Last September, the Advisory Council on the Misuse of Drugs launched a review of cannabis-based products for medical use.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button